267 related articles for article (PubMed ID: 11443562)
21. Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation - a compassionate use experience.
DeVincenzo JP; Hirsch RL; Fuentes RJ; Top FH
Bone Marrow Transplant; 2000 Jan; 25(2):161-5. PubMed ID: 10673674
[TBL] [Abstract][Full Text] [Related]
22. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group.
Subramanian KN; Weisman LE; Rhodes T; Ariagno R; Sánchez PJ; Steichen J; Givner LB; Jennings TL; Top FH; Carlin D; Connor E
Pediatr Infect Dis J; 1998 Feb; 17(2):110-5. PubMed ID: 9493805
[TBL] [Abstract][Full Text] [Related]
23. A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways.
Piedimonte G; King KA; Holmgren NL; Bertrand PJ; Rodriguez MM; Hirsch RL
Pediatr Res; 2000 Mar; 47(3):351-6. PubMed ID: 10709734
[TBL] [Abstract][Full Text] [Related]
24. Palivizumab for respiratory syncytial virus prophylaxis.
Sandritter T
J Pediatr Health Care; 1999; 13(4):191-5; quiz 196-7. PubMed ID: 10690084
[TBL] [Abstract][Full Text] [Related]
25. Respiratory syncytial virus: seasonal data for regions of Florida and implications for palivizumab.
Bauman J; Eggleston M; Oquist N; Malinoski F
South Med J; 2007 Jul; 100(7):669-76. PubMed ID: 17639745
[TBL] [Abstract][Full Text] [Related]
26. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
Hashmi NA; Cosgrove JF; MacMahon P
Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
[TBL] [Abstract][Full Text] [Related]
27. Management of infections caused by respiratory syncytial virus.
Swedish Consensus Group
Scand J Infect Dis; 2001; 33(5):323-8. PubMed ID: 11440215
[TBL] [Abstract][Full Text] [Related]
28. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
[TBL] [Abstract][Full Text] [Related]
29. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.
Giebels K; Marcotte JE; Podoba J; Rousseau C; Denis MH; Fauvel V; Laberge S
Pediatr Pulmonol; 2008 Feb; 43(2):169-74. PubMed ID: 18085710
[TBL] [Abstract][Full Text] [Related]
30. Strategies for preventing respiratory syncytial virus.
Forbes M
Am J Health Syst Pharm; 2008 Dec; 65(23 Suppl 8):S13-9. PubMed ID: 19020197
[TBL] [Abstract][Full Text] [Related]
31. [Palivizumab--a monoclonal antibody for passive immunoprophylaxis of respiratory syncytial virus infections].
Scholz H
Z Geburtshilfe Neonatol; 2000; 204(3):120-2. PubMed ID: 10909169
[TBL] [Abstract][Full Text] [Related]
32. Respiratory syncytial virus prophylaxis in Down syndrome: a prospective cohort study.
Yi H; Lanctôt KL; Bont L; Bloemers BL; Weijerman M; Broers C; Li A; Kiss A; Mitchell I; Paes B;
Pediatrics; 2014 Jun; 133(6):1031-7. PubMed ID: 24799541
[TBL] [Abstract][Full Text] [Related]
33. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion.
Meissner HC; Welliver RC; Chartrand SA; Law BJ; Weisman LE; Dorkin HL; Rodriguez WJ
Pediatr Infect Dis J; 1999 Mar; 18(3):223-31. PubMed ID: 10093942
[No Abstract] [Full Text] [Related]
34. Respiratory syncytial virus (RSV) immune globulin and palivizumab for prevention of RSV infection.
Robinson RF; Nahata MC
Am J Health Syst Pharm; 2000 Feb; 57(3):259-64. PubMed ID: 10674778
[TBL] [Abstract][Full Text] [Related]
35. Use of palivizumab to control an outbreak of syncytial respiratory virus in a neonatal intensive care unit.
Abadesso C; Almeida HI; Virella D; Carreiro MH; Machado MC
J Hosp Infect; 2004 Sep; 58(1):38-41. PubMed ID: 15350712
[TBL] [Abstract][Full Text] [Related]
36. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.
DeVincenzo JP; Hall CB; Kimberlin DW; Sánchez PJ; Rodriguez WJ; Jantausch BA; Corey L; Kahn JS; Englund JA; Suzich JA; Palmer-Hill FJ; Branco L; Johnson S; Patel NK; Piazza FM
J Infect Dis; 2004 Sep; 190(5):975-8. PubMed ID: 15295704
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD
Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
[TBL] [Abstract][Full Text] [Related]
38. Safety and immunogenicity of palivizumab (Synagis) administered for two seasons.
Null D; Pollara B; Dennehy PH; Steichen J; Sánchez PJ; Givner LB; Carlin D; Landry B; Top FH; Connor E
Pediatr Infect Dis J; 2005 Nov; 24(11):1021-3. PubMed ID: 16282947
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Palivizumab-Like Antibody Binding to Different Conformations of the RSV F Protein in RSV-Infected Adult Hematopoietic Cell Transplant Recipients.
Ye X; Iwuchukwu OP; Avadhanula V; Aideyan LO; McBride TJ; Ferlic-Stark LL; Patel KD; Piedra FA; Shah DP; Chemaly RF; Piedra PA
J Infect Dis; 2018 Mar; 217(8):1247-1256. PubMed ID: 29365155
[TBL] [Abstract][Full Text] [Related]
40. Intravenous ribavirin for respiratory syncytial viral infections in pediatric hematopoietic SCT recipients.
Molinos-Quintana A; Pérez-de Soto C; Gómez-Rosa M; Pérez-Simón JA; Pérez-Hurtado JM
Bone Marrow Transplant; 2013 Feb; 48(2):265-8. PubMed ID: 23000643
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
